Volitionrx Ltd (VNRX)

$0.46 -0.14 (-22.65%)
Market Cap 64.56M
Revenue (ttm) 1.23M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,192.68%
Debt to Equity Ratio -0.21
Volume 2,023,400
Avg Vol 255,688
Day's Range N/A - N/A
Shares Out 107.60M
Stochastic %K 1%
Beta 1.27
Analysts Strong Sell
Price Target $3.09

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices
Sector: Healthcare
Phone: 646 650 1351
Address:
1489 West Warm Springs Road, Suite 110, Henderson, United States
MeetyaMaker
MeetyaMaker Oct. 11 at 2:16 PM
$VNRX got a starter @ 0.462, fingers cross
0 · Reply
2021er
2021er Oct. 10 at 9:55 PM
$VNRX 2027 2$.. they're not failing but will take awfully long..or market/retail will earlier regonize this actual very promising tech..or they actually make a multimio deal before and werfen takes it exclusive
0 · Reply
LazyRaptor78
LazyRaptor78 Oct. 10 at 6:42 PM
$VNRX Low float + serial catalysts = velocity. One clean data print and algos chase. Latecomers become liquidity.
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 6:41 PM
$VNRX VolitionRx (stock volume 10-10-25) 0.49 −18.3% | volume 1,408,605 | 90-day avg 221,841 × 6.3
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 10 at 1:11 PM
$VNRX (-16.7% pre) VolitionRx prices $6 million public offering at $0.52 per share https://ooc.bz/l/80109
0 · Reply
UgoGreg
UgoGreg Oct. 10 at 1:10 PM
$VNRX https://youtu.be/bPH6B_B9cfw
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 10 at 12:57 PM
$VNRX
0 · Reply
DonCorleone77
DonCorleone77 Oct. 10 at 12:37 PM
$VNRX VolitionRx announces pricing of $6M offering of common stock, warrants
0 · Reply
ThatDudeWithNoMoney3
ThatDudeWithNoMoney3 Oct. 10 at 12:32 PM
$VNRX $PWM $ADAP 👇👇👇👇
0 · Reply
jetty323
jetty323 Oct. 10 at 1:49 AM
$VNRX looks like my previous post is going to turn out to be way too conservative, probably test/fall below the ATL. Regardless of how arrogant/naive I think Reynolds is they knew this offering would tank the stock and so someone who wants to buy has decided that this would be the best way to do so, aside from the fact that once again Reynolds is unable to get anything publicly done within the timeframe he has verbally committed too; he's a fukn joke as a CEO. It will either happen within the next couple of months or there will be a RS soon after. Time will tell
1 · Reply
Latest News on VNRX
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 10, 2025, 8:30 AM EDT - 1 day ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 2 days ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

VolitionRx Limited - Special Call

Oct 8, 2025, 4:56 PM EDT - 3 days ago

VolitionRx Limited - Special Call

Volition Sponsors Upcoming GenomeWeb Webinar

Oct 2, 2025, 8:45 AM EDT - 9 days ago

Volition Sponsors Upcoming GenomeWeb Webinar

Volition Signs Co-Marketing and Services Agreement with Hologic

Sep 29, 2025, 9:30 AM EDT - 12 days ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Volition Signs First Human Out Licensing Deal

Sep 9, 2025, 8:45 AM EDT - 4 weeks ago

Volition Signs First Human Out Licensing Deal

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 2:24 PM EDT - 2 months ago

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 14, 2025, 4:10 PM EDT - 2 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 8, 2025, 8:30 AM EDT - 2 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Aug 4, 2025, 4:01 PM EDT - 2 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 16, 2025, 8:00 AM EDT - 3 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jul 8, 2025, 8:00 AM EDT - 3 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 12, 2025, 8:30 AM EDT - 4 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

Jun 4, 2025, 9:00 PM EDT - 4 months ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025, 8:30 AM EDT - 5 months ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025, 7:19 PM EDT - 5 months ago

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025, 5:37 PM EDT - 5 months ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025, 8:30 AM EDT - 5 months ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025, 8:30 AM EDT - 5 months ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Apr 29, 2025, 8:30 AM EDT - 5 months ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 12:31 AM EDT - 6 months ago

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 31, 2025, 4:05 PM EDT - 6 months ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 28, 2025, 8:00 AM EDT - 7 months ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 27, 2025, 8:30 AM EDT - 7 months ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 26, 2025, 8:00 AM EDT - 7 months ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 25, 2025, 9:30 AM EDT - 7 months ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 21, 2025, 8:30 AM EDT - 7 months ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Mar 20, 2025, 8:30 AM EDT - 7 months ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Volition Proudly Sponsors the 44th ISICEM Congress

Mar 17, 2025, 8:30 AM EDT - 7 months ago

Volition Proudly Sponsors the 44th ISICEM Congress

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Mar 13, 2025, 8:30 AM EDT - 7 months ago

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Mar 11, 2025, 8:30 AM EDT - 7 months ago

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Mar 4, 2025, 8:30 AM EST - 7 months ago

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Feb 28, 2025, 8:30 AM EST - 8 months ago

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Feb 6, 2025, 8:30 AM EST - 8 months ago

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Feb 5, 2025, 9:15 AM EST - 8 months ago

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Jan 30, 2025, 8:30 AM EST - 9 months ago

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Volition Issues Business Review 2024

Jan 8, 2025, 8:30 AM EST - 9 months ago

Volition Issues Business Review 2024

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Dec 12, 2024, 8:00 AM EST - 10 months ago

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

Dec 10, 2024, 8:00 AM EST - 10 months ago

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

Dec 6, 2024, 9:00 AM EST - 11 months ago

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 11:47 AM EST - 11 months ago

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Nov 14, 2024, 4:10 PM EST - 11 months ago

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

Nov 8, 2024, 8:00 AM EST - 1 year ago

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

Volition Appoints Timothy I. Still as Chairman

Nov 6, 2024, 4:10 PM EST - 1 year ago

Volition Appoints Timothy I. Still as Chairman

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Volition Appoints Dr. Ethel Rubin as an Independent Director

Sep 30, 2024, 4:10 PM EDT - 1 year ago

Volition Appoints Dr. Ethel Rubin as an Independent Director

Volition Hosts KOL Roundtable on Sepsis

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Volition Hosts KOL Roundtable on Sepsis

VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 12:11 PM EDT - 1 year ago

VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript

MeetyaMaker
MeetyaMaker Oct. 11 at 2:16 PM
$VNRX got a starter @ 0.462, fingers cross
0 · Reply
2021er
2021er Oct. 10 at 9:55 PM
$VNRX 2027 2$.. they're not failing but will take awfully long..or market/retail will earlier regonize this actual very promising tech..or they actually make a multimio deal before and werfen takes it exclusive
0 · Reply
LazyRaptor78
LazyRaptor78 Oct. 10 at 6:42 PM
$VNRX Low float + serial catalysts = velocity. One clean data print and algos chase. Latecomers become liquidity.
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 6:41 PM
$VNRX VolitionRx (stock volume 10-10-25) 0.49 −18.3% | volume 1,408,605 | 90-day avg 221,841 × 6.3
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 10 at 1:11 PM
$VNRX (-16.7% pre) VolitionRx prices $6 million public offering at $0.52 per share https://ooc.bz/l/80109
0 · Reply
UgoGreg
UgoGreg Oct. 10 at 1:10 PM
$VNRX https://youtu.be/bPH6B_B9cfw
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 10 at 12:57 PM
$VNRX
0 · Reply
DonCorleone77
DonCorleone77 Oct. 10 at 12:37 PM
$VNRX VolitionRx announces pricing of $6M offering of common stock, warrants
0 · Reply
ThatDudeWithNoMoney3
ThatDudeWithNoMoney3 Oct. 10 at 12:32 PM
$VNRX $PWM $ADAP 👇👇👇👇
0 · Reply
jetty323
jetty323 Oct. 10 at 1:49 AM
$VNRX looks like my previous post is going to turn out to be way too conservative, probably test/fall below the ATL. Regardless of how arrogant/naive I think Reynolds is they knew this offering would tank the stock and so someone who wants to buy has decided that this would be the best way to do so, aside from the fact that once again Reynolds is unable to get anything publicly done within the timeframe he has verbally committed too; he's a fukn joke as a CEO. It will either happen within the next couple of months or there will be a RS soon after. Time will tell
1 · Reply
jetty323
jetty323 Oct. 9 at 10:34 PM
$VNRX
0 · Reply
2021er
2021er Oct. 9 at 8:33 PM
$VNRX
1 · Reply
DonCorleone77
DonCorleone77 Oct. 9 at 8:08 PM
$VNRX VolitionRx announces offering of common stock and warrants, no amount given
0 · Reply
DARKP00L
DARKP00L Oct. 9 at 8:07 PM
$VNRX 16:07 on Oct. 09 2025 VolitionRx Announces Proposed Underwritten Public Offering Of Common Stock And Common Stock Warrants; No Terms Disclosed #tradeideas
0 · Reply
Bigspydee040
Bigspydee040 Oct. 7 at 8:58 PM
$VNRX - more insider selling going on
2 · Reply
2021er
2021er Oct. 6 at 4:38 PM
$VNRX
0 · Reply
ZacksSCR
ZacksSCR Oct. 1 at 3:38 PM
$VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with $HOLX https://buff.ly/VEkieEo
0 · Reply
2021er
2021er Sep. 30 at 10:11 PM
$VNRX
0 · Reply
Bigspydee040
Bigspydee040 Sep. 30 at 9:41 PM
$VNRX - insiders were selling yesterday.
0 · Reply
SkinnyDude911
SkinnyDude911 Sep. 30 at 3:44 PM
$VNRX
0 · Reply
jetty323
jetty323 Sep. 30 at 4:33 AM
$VNRX what do you think the low will be this week? My money's on .51, though that may be conservative. the "hope fluff" of the last couple of announcements only gives fuel to sellers fire. Yet again nothing definitive, little conviction, tepid noise, ie, "we really hope this works out"!
1 · Reply
JarvisFlow
JarvisFlow Sep. 29 at 4:37 PM
D. Boral Capital has adjusted their stance on VolitionRX ( $VNRX ), setting the rating to Buy with a target price of 5.
0 · Reply